Journal
JOURNAL OF EXPERIMENTAL MEDICINE
Volume 207, Issue 3, Pages 623-635Publisher
ROCKEFELLER UNIV PRESS
DOI: 10.1084/jem.20091990
Keywords
-
Categories
Funding
- National Institutes of Health [RO1AI18697, U19AI077435, DK63363, R03CA129579]
- Crohn's and Colitis Foundation of America
- Veteran's Administration Merit Award
- Polish Ministry of Scientific Research [N401 003635]
- American Heart Association [0815066E]
- National Institutes of Health-National Institute of Neurological Disorders and Stroke Center [5P30NS047463]
Ask authors/readers for more resources
The proteolytic activity of a disintegrin and metalloproteinase 10 (ADAM10) regulates cell-fate decisions in Drosophila and mouse embryos. However, in utero lethality of ADAM10(-/-) mice has prevented examination of ADAM10 cleavage events in lymphocytes. To investigate their role in B cell development, we generated B cell-specific ADAM10 knockout mice. Intriguingly, deletion of ADAM10 prevented development of the entire marginal zone B cell (MZB) lineage. Additionally, cleavage of the low affinity IgE receptor, CD23, was profoundly impaired, but subsequent experiments demonstrated that ADAM10 regulates CD23 cleavage and MZB development by independent mechanisms. Development of MZBs is dependent on Notch2 signaling, which requires proteolysis of the Notch2 receptor by a previously unidentified proteinase. Further experiments revealed that Notch2 signaling is severely impaired in ADAM10-null B cells. Thus, ADAM10 critically regulates MZB development by initiating Notch2 signaling. This study identifies ADAM10 as the in vivo CD23 sheddase and an important regulator of B cell development. Moreover, it has important implications for the treatment of numerous CD23- and Notch-mediated pathologies, ranging from allergy to cancer.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available